[{"address1": "9708 Medical Center Drive", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "240 243 1201", "fax": "301 738 2137", "website": "https://www.glycomimetics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Mr. Harout  Semerjian", "age": 54, "title": "CEO, President & Director", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 1100695, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rachel K. King", "age": 65, "title": "Co-Founder & Director", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 40000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian M. Hahn", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 728554, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stephanie R. Irish CPA", "age": 53, "title": "Vice President of Accounting", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christian B. Dinneen-Long", "title": "General Counsel & Company Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bruce  Johnson", "age": 56, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chinmaya  Rath", "age": 47, "title": "Senior VP & Chief Business Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shantha  Tyavanagimatt Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 7, "shareHolderRightsRisk": 9, "overallRisk": 7, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 0.2838, "open": 0.29, "dayLow": 0.2727, "dayHigh": 0.2999, "regularMarketPreviousClose": 0.2838, "regularMarketOpen": 0.29, "regularMarketDayLow": 0.2727, "regularMarketDayHigh": 0.2999, "beta": 1.82, "forwardPE": -3.222222, "volume": 862860, "regularMarketVolume": 862860, "averageVolume": 734366, "averageVolume10days": 291410, "averageDailyVolume10Day": 291410, "marketCap": 18714570, "fiftyTwoWeekLow": 0.14, "fiftyTwoWeekHigh": 3.36, "priceToSalesTrailing12Months": 1871.457, "fiftyDayAverage": 0.2638, "twoHundredDayAverage": 0.2882, "currency": "USD", "enterpriseValue": 4171016, "floatShares": 42997258, "sharesOutstanding": 64533000, "sharesShort": 2034421, "sharesShortPriorMonth": 2171955, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0315, "heldPercentInsiders": 0.02871, "heldPercentInstitutions": 0.53970003, "shortRatio": 5.97, "shortPercentOfFloat": 0.0454, "impliedSharesOutstanding": 64533000, "bookValue": 0.176, "priceToBook": 1.6477273, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -39735048, "trailingEps": -0.59, "forwardEps": -0.09, "enterpriseToRevenue": 417.102, "enterpriseToEbitda": -0.114, "52WeekChange": -0.9159159, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GLYC", "underlyingSymbol": "GLYC", "shortName": "GlycoMimetics, Inc.", "longName": "GlycoMimetics, Inc.", "firstTradeDateEpochUtc": 1389364200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "efe04473-e4ee-3464-8e89-48cc4b8490b8", "messageBoardId": "finmb_5703481", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.29, "targetHighPrice": 1.0, "targetLowPrice": 1.0, "targetMeanPrice": 1.0, "targetMedianPrice": 1.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 14391664, "totalCashPerShare": 0.223, "ebitda": -36726288, "totalDebt": 262133, "quickRatio": 3.342, "currentRatio": 3.62, "totalRevenue": 10000, "debtToEquity": 2.304, "returnOnAssets": -0.66737, "returnOnEquity": -1.37197, "grossProfits": 10000, "freeCashflow": -18618764, "operatingCashflow": -35011588, "grossMargins": 1.0, "operatingMargins": -3678.4758, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]